Strumento inattivo

Altre lingue Aytu Bioscience Inc Nasdaq

Azioni

US0547544033

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024	30/05
Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15/05
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q3 Revenue $18M, vs. Street Est of $17.4M	15/05
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	14/02
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14/02
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	24/01
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M	14/11
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party	26/10/23
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement	26/10/23
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer	06/10/23
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M	27/09/23
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	27/09/23
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	27/09/23
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	27/09/23
Aytu BioPharma to Present at LD Micro Main Event XVI Conference	14/09/23
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Israel and the Palestinian Authority	01/08/23
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority	31/07/23
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement	10/07/23
AYTU BIOPHARMA, INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	12/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Aytu Bioscience Inc Nasdaq

Azioni

US0547544033

Altre lingue

Filtri